Epigral Ltd Reports ₹7.05 Billion Revenue for June Quarter

AHMEDABAD — Epigral Ltd, a prominent integrated chemical manufacturer based in Gujarat, reported its financial results for the quarter ending June 30, 2026, revealing consolidated revenue from operations of ₹7.05 billion. The company further announced a consolidated net profit of ₹997.4 million for the same period.

As the Indian chemical sector navigates shifting global demand and varying raw material costs, these figures offer a baseline for the company's performance in the first quarter of the 2027 fiscal year. The results follow a period of strategic expansion for the organization, which has been aggressively moving toward high-margin specialty derivatives to diversify its traditional Chlor-Alkali business.

Financial Performance Overview

The latest data reflects the ongoing efforts by Epigral Ltd to maintain operational resilience. By leveraging its integrated manufacturing complex in Dahej, Gujarat, the company utilizes captive power and backward integration to manage energy costs—a critical factor in the chemical manufacturing industry.

Market analysts closely monitor Epigral’s shift toward value-added products, such as Chlorinated Polyvinyl Chloride (CPVC) and Epichlorohydrin (ECH). The company currently holds the distinction of being the first in India to commission an Epichlorohydrin plant and maintains the country's largest capacity for CPVC resin, both of which are central to its long-term growth strategy.

Strategic Focus on Specialty Chemicals

Epigral Ltd has been consistently reorienting its business model to reduce reliance on commodity chemicals. According to company disclosures, the firm’s strategy involves utilizing basic chemicals like chlorine and hydrogen for the internal production of specialty derivatives.

This transition is aimed at insulating the bottom line from the volatility often seen in commodity price cycles. With a commitment to expanding its footprint in segments such as hydrogen peroxide and chloromethanes, the firm aims to cater to essential end-user industries including pharmaceuticals, textiles, and water treatment.

Impact on Stakeholders

For investors and stakeholders, the Q1 results underscore the company's ability to maintain profitability despite broader macroeconomic uncertainties. The organization’s focus on ESG (Environmental, Social, and Governance) standards, including the adoption of wind-solar hybrid power projects, is intended to lower long-term operational costs and align with sustainable industrial practices.

The company's management has previously indicated that ongoing capital expenditure projects are progressing within budget, with the goal of addressing the increasing domestic demand for specialized chemical products in India.

Key Facts at a Glance

• Revenue from Operations: The company recorded ₹7.05 billion in consolidated revenue for the quarter ended June 30, 2026.

• Consolidated Net Profit: Net profit for the period stood at ₹997.4 million.

• Manufacturing Base: Operations are centered around a fully integrated, automated facility located in Dahej, Gujarat.

• Core Competencies: The firm is a leading producer of Chlor-Alkali and derivatives, including CPVC, ECH, and hydrogen peroxide.

FAQ

What is Epigral Ltd's primary business? Epigral Ltd is an integrated chemical manufacturer specializing in the production of Chlor-Alkali and its derivatives, as well as specialty chemicals used in industries like pharmaceuticals and textiles.

Where is the company headquartered? The company is headquartered in Ahmedabad, Gujarat, India.

Is Epigral Ltd a publicly traded company? Yes, the company is listed on the National Stock Exchange (NSE) under the symbol EPIGRAL and the Bombay Stock Exchange (BSE) under the scrip code 543332.

What are the main products produced by the company? Key products include Caustic Soda, Caustic Potash, CPVC resin, Epichlorohydrin, Chloromethanes, and Hydrogen Peroxide.

Source: Epigral Ltd Corporate Filings, National Stock Exchange of India